Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Advances in Therapy
|
May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Noemi Puig, Joris Diels, Suzy van Sanden, et al.
The Lancet. Haematology
|
January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Investigative Ophthalmology & Visual Science
|
March 28, 2015
Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension
Shinwu Jeong, Nitin Patel, Christopher K Edlund, et al.
Blood Cancer Journal
|
November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4
Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
The Lancet. Oncology
|
January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
The New England Journal of Medicine
|
February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
Simon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
The New England Journal of Medicine
|
June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Jesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Advances in Therapy
|
May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Noemi Puig, Joris Diels, Suzy van Sanden, et al.
The Lancet. Haematology
|
January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Investigative Ophthalmology & Visual Science
|
March 28, 2015
Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension
Shinwu Jeong, Nitin Patel, Christopher K Edlund, et al.
Blood Cancer Journal
|
November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4
Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
The Lancet. Oncology
|
January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
The New England Journal of Medicine
|
February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
Simon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
The New England Journal of Medicine
|
June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Jesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Page
of 10